Skip to content Skip to footer
Subscribe Now
PharmaShots Interview PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
VIEWPOINTS

PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100

In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgery Shots: The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…
February 16, 2022

Read more

VIEWPOINTS

PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation

In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete. Additional programs using anti-TNF soon to…
February 15, 2022

Read more

Exclusive_John Meduri_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and worldwide. He also shared his views on Accelerate Pheno system and PhenoTest BC kit. Shots: Antibiotic resistance occurs when bacteria develop the ability to defeat…
February 14, 2022

Read more

PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate Cancer Shots: The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…
February 9, 2022

Read more

Viewpoints_Philip M. Brown
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM

In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque Psoriasis Shots: The P-III (PSOARING 1 & 2) trials evaluate the efficacy and safety of tapinarof (1%, qd) vs vehicle-controlled cream in a ratio (2:1) in 1025 patients aged…
February 8, 2022

Read more

EXCLUSIVE

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

In an interview with PharmaShots, Moshe Safran, CEO at RSIP Vision shared his views on the new coronary module in the complete 3D reconstruction of the coronary vasculature during angiography Shots: The company reported the 3D reconstruction technology that focused on AI to generate 3D models of patient anatomy from 2D images. The purpose of the technology is to create precise,…
February 7, 2022

Read more

Viewpoints_Laura Dix
VIEWPOINTS

PharmaShots Interview: Accenture Life Sciences’ Laura Dix Shares Insights on the New Rules of Engagement to Provide HCPs New Interactions

In an interview with PharmaShots, Laura Dix, a Managing Director in Accenture’s Life Sciences Strategy and Consulting practice shares her views on the new research & provides more useful, data-driven information to HCPs  Shots: The company unveiled new research, titled The “New” Rules of Engagement & which have increased their relevance during COVID-19 through more valuable and meaningful interactions with…
February 2, 2022

Read more

Viewpoints_Laurent Levy
VIEWPOINTS

PharmaShots Interview: Nanobiotix’s Laurent Levy Shares Insights on the P-III (NANORAY-312) Study of NBTXR3 for the Treatment of Head and Neck Squamous Cell Carcinoma

In an interview with PharmaShots, Laurent Levy, Co-Founder & CEO at Nanobiotix shares his views on the first patient enrollment of NBTXR3 in P-III (NANORAY-312) study for the treatment of head and neck squamous cell carcinoma Shots: The first patient has been enrolled in P-III (NANORAY-312) study to evaluate the efficacy & safety of NBTXR3 with/out cetuximab vs radiotherapy with/out cetuximab…
January 31, 2022

Read more

Load more